CVS Health (CVS) PT Set at $89.00 by Royal Bank of Canada

CVS Health (NYSE:CVS) received a $89.00 price target from investment analysts at Royal Bank of Canada in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the pharmacy operator’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 28.26% from the company’s current price.

Several other equities research analysts have also recently weighed in on CVS. Needham & Company LLC reiterated a “hold” rating on shares of CVS Health in a report on Thursday, October 12th. SunTrust Banks set a $85.00 target price on CVS Health and gave the stock a “buy” rating in a report on Thursday, October 12th. Jefferies Group set a $86.00 target price on CVS Health and gave the stock a “hold” rating in a report on Wednesday, October 18th. Mizuho set a $90.00 target price on CVS Health and gave the stock a “buy” rating in a report on Tuesday, October 24th. Finally, Robert W. Baird reiterated a “hold” rating and issued a $77.00 target price on shares of CVS Health in a report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $87.77.

Shares of CVS Health (NYSE:CVS) traded down $1.16 during trading on Thursday, reaching $69.39. The company’s stock had a trading volume of 16,717,348 shares, compared to its average volume of 8,720,000. The company has a market cap of $70,290.00, a P/E ratio of 11.76, a PEG ratio of 1.18 and a beta of 0.92. The company has a quick ratio of 0.55, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.00.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The business had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. During the same period in the prior year, the business earned $1.71 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. equities analysts anticipate that CVS Health will post 6.49 EPS for the current year.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.61% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Mission Wealth Management LP increased its position in CVS Health by 28.3% during the 4th quarter. Mission Wealth Management LP now owns 3,445 shares of the pharmacy operator’s stock valued at $250,000 after buying an additional 759 shares in the last quarter. Gould Asset Management LLC CA increased its position in CVS Health by 19.7% during the 4th quarter. Gould Asset Management LLC CA now owns 6,085 shares of the pharmacy operator’s stock valued at $441,000 after buying an additional 1,000 shares in the last quarter. Timber Hill LLC increased its position in CVS Health by 102.8% during the 4th quarter. Timber Hill LLC now owns 9,736 shares of the pharmacy operator’s stock valued at $706,000 after buying an additional 4,936 shares in the last quarter. GM Advisory Group Inc. acquired a new position in CVS Health during the 4th quarter valued at about $222,000. Finally, Smith Moore & CO. increased its position in CVS Health by 19.5% during the 4th quarter. Smith Moore & CO. now owns 7,083 shares of the pharmacy operator’s stock valued at $514,000 after buying an additional 1,157 shares in the last quarter. Hedge funds and other institutional investors own 81.69% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/10/cvs-health-cvs-pt-set-at-89-00-by-royal-bank-of-canada.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply